US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...

For the first time, researchers have found evidence of a biological cause for the impairments caused by the disease ...

More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® ...

Patients with schizophrenia have a lot of life-changing consequences when they are being treated properly, and these are only amplified when the patient goes untreated, explained Megan Ehret, PharmD, ...

A better understanding of the lived experience of people with schizophrenia would enable clinicians to help patients live with their condition, alongside treating symptoms with medication and ...

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the ...

Since the birth of psychotherapy with Freud, most therapists have avoided treating patients with schizophrenia. Freud's original conceptualization of the disease was as a narcissistic neurosis. He ...